Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 33856403.
- Also identified by DOI 10.1001/jamaoncol.2021.0546 and PMC identifier 8050787.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cohort study examines the association of <i>KRAS</i> status with outcomes following immune checkpoint inhibition monotherapy vs chemoimmunotherapy.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms